CA
ABBV icon

Cullinan Associates’s AbbVie ABBV Stock Holding History

Cullinan Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16M Sell
73,455
-9,920
-12% -$2.2M 1.29% 19
2025
Q4 		$19.1M Sell
83,375
-1,411
-2% -$321K 1.29% 18
2025
Q3 		$19.6M Sell
84,786
-3,357
-4% -$684K 1.28% 21
2025
Q2 		$16.4M Sell
88,143
-3,573
-4% -$664K 1.08% 25
2025
Q1 		$19.2M Sell
91,716
-2,061
-2% -$401K 1.36% 20
2024
Q4 		$16.7M Sell
93,777
-15,625
-14% -$2.87M 1.07% 25
2024
Q3 		$20.4M Sell
109,402
-11,206
-9% -$2.09M 1.15% 24
2024
Q2 		$20.7M Sell
120,608
-6,508
-5% -$1.08M 1.17% 24
2024
Q1 		$23.1M Sell
127,116
-3,295
-3% -$568K 1.3% 20
2023
Q4 		$20.2M Sell
130,411
-20,680
-14% -$3.01M 1.13% 21
2023
Q3 		$22.5M Buy
151,091
+13,226
+10% +$1.94M 1.31% 18
2023
Q2 		$18.6M Buy
137,865
+5,261
+4% +$771K 1.02% 21
2023
Q1 		$21.1M Buy
132,604
+7,080
+6% +$1.08M 1.23% 18
2022
Q4 		$20.3M Buy
125,524
+3,947
+3% +$605K 1.12% 14
2022
Q3 		$16.3M Sell
121,577
-3,714
-3% -$533K 1.03% 22
2022
Q2 		$19.2M Buy
125,291
+8,145
+7% +$1.24M 1.17% 16
2022
Q1 		$19M Sell
117,146
-10,297
-8% -$1.5M 1% 24
2021
Q4 		$17.3M Buy
127,443
+36,841
+41% +$4.35M 0.88% 31
2021
Q3 		$9.77M Buy
90,602
+12,353
+16% +$1.41M 0.54% 52
2021
Q2 		$8.81M Buy
78,249
+23,757
+44% +$2.68M 0.49% 62
2021
Q1 		$5.9M Buy
54,492
+40,661
+294% +$4.35M 0.34% 82
2020
Q4 		$1.48M Buy
13,831
+6,700
+94% +$644K 0.09% 119
2020
Q3 		$625K Sell
7,131
-1,800
-20% -$169K 0.04% 132
2020
Q2 		$877K Buy
8,931
+2,031
+29% +$179K 0.06% 124
2020
Q1 		$526K Sell
6,900
-4,800
-41% -$409K 0.04% 127
2019
Q4 		$1.04M Sell
11,700
-400
-3% -$33.2K 0.07% 126
2019
Q3 		$916K Buy
12,100
+1,900
+19% +$130K 0.07% 129
2019
Q2 		$742K Sell
10,200
-1,300
-11% -$102K 0.05% 135
2019
Q1 		$927K Buy
11,500
+3,330
+41% +$272K 0.07% 131
2018
Q4 		$753K Hold
8,170
– – 0.06% 133
2018
Q3 		$773K Sell
8,170
-1,600
-16% -$152K 0.06% 134
2018
Q2 		$905K Buy
9,770
+300
+3% +$29.3K 0.07% 132
2018
Q1 		$896K Buy
9,470
+2,500
+36% +$275K 0.07% 133
2017
Q4 		$674K Sell
6,970
-14,700
-68% -$1.39M 0.05% 150
2017
Q3 		$1.93M Sell
21,670
-2,000
-8% -$152K 0.15% 115
2017
Q2 		$1.72M Buy
23,670
+200
+0.9% +$13.4K 0.13% 122
2017
Q1 		$1.53M Buy
23,470
+330
+1% +$20.7K 0.12% 123
2016
Q4 		$1.45M Sell
23,140
-90,560
-80% -$5.53M 0.12% 127
2016
Q3 		$7.17M Buy
113,700
+1,200
+1% +$77.7K 0.61% 40
2016
Q2 		$6.96M Buy
112,500
+13,750
+14% +$838K 0.57% 44
2016
Q1 		$5.64M Buy
98,750
+12,400
+14% +$691K 0.48% 57
2015
Q4 		$5.12M Sell
86,350
-13,830
-14% -$797K 0.45% 56
2015
Q3 		$5.45M Buy
100,180
+19,550
+24% +$1.27M 0.5% 51
2015
Q2 		$5.42M Sell
80,630
-1,190
-1% -$77.7K 0.45% 54
2015
Q1 		$4.79M Buy
+81,820
New +$4.94M 0.37% 61

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cullinan Associates's ABBV Position: Q1 2026 in Review

Cullinan Associates reduced its AbbVie (ABBV) stake by 12% in Q1 2026, selling an estimated $2.2M and leaving 73,455 shares worth $16M. The position accounts for 1.29% of the portfolio, ranked #19.

Cullinan Associates first reported a position in ABBV in Q1 2015 and has held it in 45 quarters since. The position peaked at $23.1M in Q1 2024. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Cullinan Associates held 73,455 shares of AbbVie worth $16M as of Q1 2026.
  • Cullinan Associates sold 9,920 AbbVie shares in Q1 2026, an estimated $2.2M.
  • AbbVie made up 1.29% of Cullinan Associates's portfolio in Q1 2026, its #19 holding.
  • Cullinan Associates first reported a position in AbbVie in Q1 2015 and has held it in 45 quarters since.
  • Cullinan Associates's AbbVie position peaked at $23.1M in Q1 2024.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Cullinan Associates's 13F filing for Q1 2026, filed 1 May 2026.